Overview of current pharmacotherapeutic options in benign prostatic hyperplasia

Koudonas, Antonios; Anastasiadis, Anastasios; Tsiakaras, Stavros; Langas, Georgios; Savvides, Eliophotos; Mykoniatis, Ioannis; Memmos, Dimitrios; Baniotis, Panagiotis; Vakalopoulos, Ioannis; Rosette, Jean de la; Dimitriadis, G.

doi:10.1080/14656566.2023.2237406

Cited by 4 publications

(2 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The surgical treatment methods for BPH can be broadly divided into traditional open surgery and minimally invasive surgery, with open surgery being rarely performed due to reasons such as large incisions, high intraoperative blood loss, high incidence of postoperative complications, and long hospital stay. With the continuous development of minimally invasive techniques, transurethral prostate resection has gradually been applied to patients with BPH and has become the gold standard for clinical treatment of this disease due to its characteristics such as minimal trauma, clear surgical eld, and minimal blood loss [21].…”

Section: Discussionmentioning

confidence: 99%

The clinical efficacy of transurethral prostate resection in patients with Benign Prostatic Hyperplasia

Cao,

Yao,

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Benign prostatic hyperplasia (BPH) is a common urological disease in middle-aged and elderly men. Currently, two surgical methods are commonly used in clinical practice: transurethral plasma resection of the prostate (TUPKEP) and transurethral resection of the prostate (TURP). However, the specific advantages and disadvantages of the two surgeries still need to be further explored. Objective This study aims to analyze the clinical efficacy of TUPKEP and TURP treatments in patients with BPH, in order to find the best surgical approach. Methods 240 patients with BPH were selected and divided into a TUPKEP group and a TURP group based on surgical methods, with 120 cases in each group. The TUPKEP group received TUPKEP, while the TURP group received TURP. Compare the therapeutic effects of two groups. Results Compared with TUPKEP group, the levels of prostate specific antigen (PSA) in the TURP group were lower (P < 0.001), and the International Erectile Function Questionnaire-5 (IIEF-5) scores were higher (P < 0.01); There was no significant difference in the incidence of complications between the two groups (P > 0.05). Conclusion Compared with TUPKEP group, TURP treatment of BPH has better clinical efficacy, and the complication rate is basically the same.

show abstract

Section: Discussionmentioning

confidence: 99%

The clinical efficacy of transurethral prostate resection in patients with Benign Prostatic Hyperplasia

Cao,

Yao,

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In the prostate, hyperactivity of these cells is linked to benign prostatic hyperplasia, leading to an enlarged prostate that may obstruct urinary flow [5]. One of the current treatments for these conditions targets the inhibition of smooth muscle contraction via α1-adrenergic receptors [4][5][6]. Therefore, we aimed to examine the effect of EO on rat prostate and aorta and to explore whether the effect is related to α 1 -adrenergic receptors.…”

Section: Introductionmentioning

confidence: 99%

Elsholtzia ciliata Essential Oil Exhibits a Smooth Muscle Relaxant Effect

Martišienė,

Zigmantaitė,

Pudžiuvelytė

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

A recent in vivo study in pigs demonstrated the hypotensive properties of essential oil extracted from the blossoming plant Elsholtzia ciliata. This study was designed to examine the effect of E. ciliata essential oil (EO) on smooth muscle contraction. Tension measurements were performed on prostate strips and intact aortic rings isolated from rats. Results showed that EO caused a concentration-dependent reduction in phenylephrine-induced contraction of both the prostate and aorta, with a more pronounced inhibitory effect in the prostate. The IC50 of EO for the prostate was 0.24 ± 0.03 µL/mL (n = 10) and for the aorta was 0.72 ± 0.11 µL/mL (n = 4, p < 0.05 vs. prostate). The chromatographic analysis identified elsholtzia ketone (10.64%) and dehydroelsholtzia ketone (86.23%) as the predominant compounds in the tested EO. Since both compounds feature a furan ring within their molecular structure, other furan ring-containing compounds, 2-acetylfuran (2AF) and 5-methylfurfural (5MFF), were examined. For the first time, our study demonstrated the relaxant effects of 2AF and 5MFF on smooth muscles. Further, results showed that EO, 2AF, and 5MFF altered the responsiveness of prostate smooth muscle cells to phenylephrine. Under control conditions, the EC50 of phenylephrine was 0.18 ± 0.03 µM (n = 5), while in the presence of EO, 2AF, or 5MFF, the EC50 values were 0.81 ± 0.3 µM (n = 5), 0.89 ± 0.11 µM (n = 5), and 0.69 ± 0.23 µM (n = 4), respectively, p < 0.05 vs. control. Analysis of the affinity of EO for α1-adrenergic receptors in the prostate suggested that EO at a certain range of concentrations has a competitive antagonistic effect on α1-adrenergic receptors. In conclusion, EO elicits a relaxant effect on smooth muscles which may be related to the inhibition of α1-adrenoreceptors.

show abstract